EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact

Rebecca Schou Jurlander, Troels Holz Borch, Søren Kjær Petersen, Marco Donia, Louise Guldbrandt, Rasmus Friis, Adam Andrzej Luczak, Henrik Schmidt, Christina Ruhlmann, Lars Bastholt, Eva Ellebaek, Inge Marie Svane

European Journal of Cancer · 2026-10 · 117789

DOI: 10.1016/j.ejca.2026.117789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-10. Verfasst von Rebecca Schou Jurlander und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Anti-PD1Combination immunotherapyEarly discontinuationImmunotherapyMelanomaReal-world evidence

Autor:innen und Institutionen

  • National Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark.
  • Department of Oncology, Odense University Hospital, Denmark.
  • Department of Oncology, Aarhus University Hospital, Denmark.
  • Department of Oncology, Aalborg University Hospital, Denmark.
  • National Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark. Electronic address: inge.marie.svane@regionh.dk.

Zitieren

APA

Jurlander, R. S., Borch, T. H., Petersen, S. K., Donia, M., Guldbrandt, L., Friis, R., Luczak, A. A., Schmidt, H., Ruhlmann, C., Bastholt, L., Ellebaek, E., & Svane, I. M. (2026). Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact. European Journal of Cancer, 117789. https://doi.org/10.1016/j.ejca.2026.117789

Vancouver

Jurlander RS, Borch TH, Petersen SK, Donia M, Guldbrandt L, Friis R, et al. Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact. European Journal of Cancer. 2026:117789. doi:10.1016/j.ejca.2026.117789

BibTeX
@article{Jurlander2026,
  author = {Jurlander, Rebecca Schou and Borch, Troels Holz and Petersen, Søren Kjær and Donia, Marco and Guldbrandt, Louise and Friis, Rasmus and Luczak, Adam Andrzej and Schmidt, Henrik and Ruhlmann, Christina and Bastholt, Lars and Ellebaek, Eva and Svane, Inge Marie},
  title = {Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: Clinical and economic impact},
  journal = {European Journal of Cancer},
  year = {2026},
  pages = {117789},
  doi = {10.1016/j.ejca.2026.117789}
}
Kostenlos starten →